KRAS and non-small cell lung carcinoma: Oncogenic mutations in key MAPK components drive up to 30% of human cancers, particularly NSCLC, which is frequently initiated by mutually exclusive mutations in RTKs such as EGFR, HER2, ALK, ROS1, KRAS, and BRAF (45–48).